— Fanapt® Q2 2025 net product sales increased by 27% to $29.3 million compared to Q2 2024 — Bysanti™(milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026 — Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025 — […]

— Announces 2025 second-quarter reported earnings (GAAP) per share of $0.25. — Achieves 2025 second-quarter ongoing earnings per share of $0.32 versus $0.38 in 2024, with lower results primarily due to timing and weather. — Reaffirms 2025 ongoing earnings forecast range of $1.75 to $1.87 per share; expects to achieve at least the midpoint of

Study results support advancing SGX945 in this difficult to treat orphan disease Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,announced today that it has completed its Phase 2a proof of concept study evaluating SGX945

Continued year-over-year sales growth driven by aerospace & defense Aerospace and defense sales of $762 million, representing 67% of Q2 2025 sales Strong demand for commercial jet engines – YoY sales growth of 27% Raising mid-point of full year adjusted earnings and cash flow guidance Second Quarter 2025 GAAP Financial Results — Sales of $1.14

Mohegan Tribal Gaming Authority, or Mohegan, will host a conference call regarding its third quarter fiscal 2025 operating results on Thursday, August7, 2025, at 11:00 a.m. (Eastern Time). Those interested in participating in the call should dial as follows: (877) 407-0890+1(201) 389-0918 (International) A live stream and subsequent replay of the call will also be

Southern Company today reported second-quarter earnings of $0.9 billion, or $0.80 per share, in 2025 compared with earnings of $1.2 billion, or $1.10 per share, in the second quarter of 2024. For the six months ended June 30, 2025, Southern Company reported earnings of $2.2 billion, or $2.01 per share, compared with $2.3 billion, or

MPLX LP (NYSE: MPLX) today announced it has entered into a definitive agreement to acquire Northwind Delaware Holdings LLC (Northwind Midstream) for $2.375 billion in cash consideration, subject to customary purchase price adjustments. MPLX intends to finance the acquisition with debt. The transaction is expected to be immediately accretive to distributable cash flow and represents

— Net sales of $2.6 billion, down 18.8% year-over-year — Reported earnings per share of $4.22 and adjusted earnings per share(1) of $1.35 — Strong year-to-date free cash flow generation — Full-year net sales and adjusted earnings per share outlook raised AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study GlobeNewswire July 31, 2025 PHILADELPHIA and VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces the

(NASDAQ:DYAI), JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced the